What are validated endpoints for lupus?
Best insight from top research papers
Validated endpoints for lupus include the Lupus Low Disease Activity State (LLDAS), which has been established as a feasible and protective target for systemic lupus erythematosus (SLE) treatment and clinical trials . LLDAS attainment has shown significant associations with reduced disease flares and irreversible end-organ damage accrual in SLE patients, making it a valuable endpoint for monitoring disease activity and treatment efficacy . The development and validation of LLDAS represent a crucial step towards improving outcomes and guiding therapeutic interventions in SLE, addressing the need for reliable endpoints in complex multiorgan conditions like lupus .
Answers from top 5 papers
More filters
| Papers (5) | Insight |
|---|---|
35 Citations | Validated endpoints for lupus nephritis include new or progressive chronic kidney disease, severe kidney injury, and the need for renal replacement therapy, predicted using short-term kidney responses. |
| Validated endpoints for lupus are lacking, contributing to failed trials. The absence of well-established targets hinders progress in systemic lupus erythematosus treatment. | |
16 Aug 2019 | The Lupus Low Disease Activity State (LLDAS) is a validated endpoint for systemic lupus erythematosus, associated with reduced disease flares and organ damage, impacting clinical practice and trial outcomes. |
| Validated endpoints for lupus include the Lupus Low Disease Activity State (LLDAS), which is associated with improved outcomes, protective from flare, damage accrual, low quality of life, and mortality. | |
01 Oct 2019 63 Citations | The Lupus Low Disease Activity State (LLDAS) has been validated as an endpoint for systemic lupus erythematosus, showing significant protection against flare and damage accrual in patients. |
Related Questions
What are the current controversies in systemic lupus erythematosus vasculitis?4 answersCurrent controversies in systemic lupus erythematosus (SLE) vasculitis revolve around the diverse manifestations of vascular injury in SLE patients. Vasculitis in SLE can present in various forms, including isolated cutaneous lesions, single organ involvement, or multiorgan system disease. The diagnosis of vasculitis in SLE is often clinical, lacking histologic confirmation, which complicates determining its true incidence. Additionally, noninflammatory vasculopathies, such as endothelial cell injury leading to vessel wall thickening and microinfarcts, are observed in SLE, with some cases associated with anti-phospholipid antibodies. These controversies highlight the need for further research to better understand the pathogenesis, diagnosis, and management of vasculitis and vasculopathies in SLE patients.
What are the biomarkers of lupus?4 answersBiomarkers of lupus, specifically systemic lupus erythematosus (SLE), encompass a range of genetic, biological, and molecular indicators used for diagnosis, disease activity assessment, and prognosis. These biomarkers include genetic susceptibility markers like mannose-binding lectin and cytokines, diagnostic markers such as anti-dsDNA antibodies, and disease activity markers like complement components and cytokines. Additionally, promising biomarkers for lupus nephritis (LN) include MCP-1, TWEAK, NGAL, and uric acid for diagnosis, while IL-6, IL-17, and IFNα are indicative of disease activity. Furthermore, urine ALCAM, CD163, and VCAM-1 show potential for LN surveillance, and NGAL is highlighted as a versatile biomarker for SLE. These biomarkers collectively aid in enhancing the management of lupus by enabling precise diagnosis, disease monitoring, and prognostic assessment.
What are the different statistics used to validate the projection of LULC?4 answersDifferent statistics used to validate the projection of LULC include overall agreement, kappa statistics, correctness, completeness, and quality indexes. The overall agreement measures the similarity between the actual and projected LULC maps, with higher values indicating greater accuracy. Kappa statistics assess the reliability of the calibration process, with higher values indicating higher data reliability. Correctness, completeness, and quality indexes are used to evaluate the accuracy and quality of the predicted LULC maps, with higher values indicating better performance. These statistics are important for validating the accuracy and reliability of LULC projections, ensuring that the models used for prediction are capable of providing accurate future scenarios.
What are the targets for lupus?5 answersThe targets for lupus include Toll-like receptors (TLRs) such as TLR2/4, TLR5, TLR3, and TLR7/8/9, which are involved in the recognition of self-molecules and have been implicated in the pathogenesis of systemic lupus erythematosus (SLE). B cells and plasma cells have also been targeted, with drugs like belimumab, rituximab, and obinutuzumab showing promise in altering B cell activity and depletion. In addition, inflammatory cytokines, chemokines, and their receptors, as well as intracellular signaling pathways, have been targeted for SLE treatment. Other potential targets include T/B cell co-stimulation molecules, complement molecules, T lymphocytes, and plasmacytoid dendritic cells. The development of targeted therapies for SLE aims to achieve disease modification and personalized treatment strategies, with the need for companion biomarkers to better characterize SLE heterogeneity and optimize treatment selection.
How to derive use cases for validaiton?5 answersUse cases can be derived for validation by following a systematic approach. First, the requirements of the software system need to be understood and documented. This can be done using techniques such as the Unified Modeling Language (UML) use case notation. Use cases provide a user perspective of the system behavior and describe interactions between external users and the system. Once the use cases are defined, scenarios can be created to validate them. Scenarios are examples of system execution that can be used to validate the use cases. These scenarios can be derived from the use cases themselves and can help ensure that the system behaves as expected. Additionally, techniques such as process mining can be used to validate use cases by analyzing real-world data and comparing it to the expected behavior.
Can rheumatoid factor be positive in lupus sle?3 answersRheumatoid factor (RF) can be positive in systemic lupus erythematosus (SLE) patients. In a study by Feldman et al., it was found that some SLE patients had positive RF, with titers of at least 1:40, while others had inconsistent or negative results. However, the presence of RF did not have a significant protective effect against the development of nephritis in SLE patients, as observed in a study by Turner-Stokes et al.. It is important to note that RF positivity in SLE can lead to difficulties in diagnosis, as it is also seen in rheumatoid arthritis (RA). Therefore, the concurrence of RA and SLE can occur, and the judicious application of diagnostic criteria is necessary to differentiate between the two conditions.